Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesLuteinizing hormone-releasing hormone agonists in the treatment of breast cancer
Expert Opinion in Pharmacotherapy, 10/19/09
Hackshaw A – This article reviews the use of luteinizing–hormone–releasing hormone (LHRH) agonists in pre– or perimenopausal women with hormone–receptor–positive breast cancer. Estimates of efficacy from systematic reviews, based on several randomized trials, are provided. These show that LHRH agonists can reduce the risk of recurrence and death, and can be an alternative to chemotherapy, particularly for women who would like to avoid early menopause. The benefits can be seen 10 or 15 years later.
Related Articles
Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer
Annals of Oncology, 11/04/09
Relevance Score: 67%
Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Cancer Epidemiology, Biomarkers & Prevention, 10/23/09
Relevance Score: 67%
Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging
The American Journal of Surgery, 10/07/09
Relevance Score: 67%
The predictive value of incidental PET/CT findings suspicious for breast cancer in women with non-breast malignancies
The American Journal of Surgery, 10/06/09
Relevance Score: 67%
A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China
Medical Oncology, 10/01/09
Relevance Score: 67%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Woman Previously Treated with Chemotherapy for Advanced Breast Cancer
Genentech, 12/15/09
Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer
The Journal of Thoracic and Cardiovascular Surgery, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor